NCT06840821View on ClinicalTrials.gov

Evaluating the Safety, Tolerability, and Preliminary Anti-tumor Activity of MB0151 in Adult Subjects With Advanced Solid Tumors Expressing Somatostatin Receptors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

156

Participants

Timeline

Start Date

May 8, 2025

Primary Completion Date

July 4, 2028

Study Completion Date

July 4, 2028

Conditions
Advanced Solid Tumors
Interventions
DRUG

MB0151 for injection

In this study, the protocol of accelerated titration combined with i3+3 is used for dose escalation. administered intravenously every 2 weeks .

Trial Locations (1)

250117

RECRUITING

Cancer Hospital Affiliated to Shandong First Medical University, Jinan

All Listed Sponsors
lead

Mainline Biosciences (Shanghai) Co., Ltd

OTHER